[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362799-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362799-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unlocking-kras-navigating-its-molecular-biology-and-treatment-landscape-among-gastrointestinal-malignancies","Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies","","KRAS-targeted therapy is transforming oncology, with numerous trials underway for KRAS-specific treatments in gastrointestinal (GI) malignancies. This review summarizes the current and emerging KRAS treatment landscape, linking KRAS biology to pancreatic, colorectal, and other GI cancers. It highlights clinical trials and future directions, including KRAS on- and off-inhibitors and variant-focused drugs targeting G12D and G12V, as well as pan/multi-KRAS inhibitors with preclinical success. It also covers KRAS T-cell therapies, vaccines, and combination immunotherapy strategies, and discusses challenges and key research gaps.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unlocking-kras-navigating-its-molecular-biology-and-treatment-landscape-among-gastrointestinal-malignancies/362799/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unlocking-kras-navigating-its-molecular-biology-and-treatment-landscape-among-gastrointestinal-malignancies/362799.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is KRAS an important driver in gastrointestinal cancers?","Question",{"text":63,"@type":64},"KRAS is an oncogenic driver that is frequently mutated across malignancies. In GI cancers, it is mutated in a high proportion of pancreatic ductal adenocarcinoma and a substantial subset of colorectal cancer cases.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the review cover about KRAS-targeted therapies?",{"text":68,"@type":64},"It summarizes current and emerging treatments, including KRAS on- and off-inhibitors, variant-focused inhibitors for mutations such as G12D and G12V, and pan/multi-KRAS inhibitors supported by preclinical results.",{"name":70,"@type":61,"acceptedAnswer":71},"Why do KRAS therapies sometimes fail or become less effective?",{"text":72,"@type":64},"Responses can be temporary because tumors adapt and develop resistance. The review discusses how mutation subtype, co-mutation landscape, and the tumor microenvironment collectively influence therapeutic vulnerability and resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362799,1790329995,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":99,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Review  \nUnlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies  \nAustin Frisch 1,*, Eric Martin 1, Timothy Cannon 2, Raymond Wadlow 2, Srivatsan Raghavan 3,4, Triparna Sen 5 and Nagla Abdel Karim 6, *  \nReceived: 12 January 2026  \nRevised: 14 February 2026  \nAccepted: 26 February 2026  \nPublished: 3 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA  \n2 Inova Schar Cancer Center, Inova Fairfax Hospital, Fairfax, VA 22042, USA;  \n[raymond.wadlow@inova.org](raymond.wadlow@inova.org) (R.W.)  \n3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA  \n4 Harvard Medical School, Boston, MA 02115, USA  \n5 Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA; [triparna.sen@osumc.edu](triparna.sen@osumc.edu)  \n6 George Washington (GW) Cancer Center, Washington, DC 20037, USA  \n* Correspondence: [austin.frisch@inova.org](austin.frisch@inova.org) (A.F.); [nkarim@mfa.gwu.edu](nkarim@mfa.gwu.edu) (N.A.K.)  \nSimple Summary  \nKirsten Rat Sarcoma Viral Oncogene (KRAS) is one of the most commonly mutated cancer genes in gastrointestinal cancers, especially pancreatic and colorectal cancer. For many years, KRAS was considered “undruggable,” meaning it could not be directly targeted with medications. Recently, new drugs have been developed that can block specific KRAS mutations, leading to promising results in some patients. However, responses are often temporary because tumors adapt and develop resistance. The effectiveness of KRAStargeted therapies depends on the specific mutation, the type of cancer, and the tumor’s surrounding environment. This review explains how KRAS works, summarizes current and emerging treatments, and discusses why some therapies succeed while others fail. We highlight the importance of combining KRAS inhibitors with other treatments and tailoring therapy to the specific biology of each cancer. Continued research is needed to improve long-term outcomes for patients with KRAS-mutated gastrointestinal cancers.  \nAbstract  \nKRAS-targeted therapy has opened new doors in the world of oncology, and many trials are underway for KRAS specific treatments for gastrointestinal (GI) malignancies. Outlining the current state of KRAS therapy and the remaining research gaps pertaining to these deadly cancers is crucial for the development of future therapeutics. In this review, we focus on the relationship between KRAS and GI malignancies. Current therapies are discussed with an in-depth exploration of the KRAS gene and how it connects to pancreatic, colorectal and other GI malignancies. Promising clinical trials and future therapies are highlighted while discussing the molecular biology behind them. Specifically, trials focusing on upcoming KRAS on and off inhibitors in development as well as variant focused inhibitors targeting the more common mutations G12D and G12V. We discuss exciting new pan/multi KRAS inhibitors that have been successful in pre-clinical trials. More unique therapeutic options include KRAS T cell therapies, vaccines, and combination strategies with immunotherapy. Furthermore, we address the difficulties with KRAS therapy, and the potential future directions needed to overcome them. An in-depth current literature review was done along with a review of the active clinical trials for KRAS-targeted therapeutics involving GI malignancies.  \nKeywords: KRAS; gastrointestinal malignancy; pancreatic cancer; colorectal cancer; resistance  \n1. Introduction  \nKirsten Rat Sarcoma Viral Oncogene (KRAS) is an oncogenic driver gene that comes from a family of genes whose protein products drive cell growth and survival. Mutations in the RAS gene family are ","cbCaimBm0Nlq0p0m","https://ap.wps.com/l/cbCaimBm0Nlq0p0m","pdf",1609965,24,"English","# Introduction\n## KRAS in gastrointestinal malignancies\n# Molecular Biology of KRAS\n## Signaling pathways and cellular processes","[{\"question\":\"Why is KRAS an important driver in gastrointestinal cancers?\",\"answer\":\"KRAS is an oncogenic driver that is frequently mutated across malignancies. In GI cancers, it is mutated in a high proportion of pancreatic ductal adenocarcinoma and a substantial subset of colorectal cancer cases.\"},{\"question\":\"What does the review cover about KRAS-targeted therapies?\",\"answer\":\"It summarizes current and emerging treatments, including KRAS on- and off-inhibitors, variant-focused inhibitors for mutations such as G12D and G12V, and pan/multi-KRAS inhibitors supported by preclinical results.\"},{\"question\":\"Why do KRAS therapies sometimes fail or become less effective?\",\"answer\":\"Responses can be temporary because tumors adapt and develop resistance. The review discusses how mutation subtype, co-mutation landscape, and the tumor microenvironment collectively influence therapeutic vulnerability and resistance.\"}]","Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies | PDF",1790149118,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/255902d15dbc1110ba9dd6eb640fe335.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f7b8dfc0748f415decead89d268936a.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b64832404208b1bc3146eb6663bc2a9e.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35192a48111b7350c6529309dedfc79.webp",980,1385]